Related Experiment Video
Updated: Aug 16, 2026
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the
Mark A Damante1, Ryan B Juncker2, Andrew S Little3
1Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Purpose:
Targeted therapy for BRAF V600E mutant papillary craniopharyngioma (PCP) has been rapidly accepted, though given the rarity of the tumor, there is limited guidance for appropriate use. Here, we retrospectively evaluated current practice patterns for the implementation of targeted therapeutics and their outcomes in the treatment of papillary craniopharyngioma (PCP).
Methods:
Practice patterns at the institutions in the Registry for Adenomas of the Pituitary and Related Disorders (RAPID) for treatment of BRAF V600E mutated PCPs using targeted therapy were evaluated. Baseline clinical and demographic variables were retrospectively recorded. Imaging response was evaluated. Dosing, treatment course, adverse events (AEs) and other therapeutic strategies employing BRAF/MEK inhibitors were studied. Adjuvant and/or salvage therapies, including radiation and surgery were recorded.
Results:
Most patients demonstrated at least partial response to BRAF and/or BRAF/MEK inhibition (13/19, 72.2%). No patients progressed through therapy. Grade 0-2 AEs occurred in 79% of cases, and nine (47.4%) patients eventually discontinued therapy. Radiation-sparing regimens demonstrated similar radiographic response rates and had smaller residual tumor volume after treatment completion (23.7 vs. 612.4 mm3, p = 0.040) compared to those receiving radiation. BRAF monotherapy demonstrated similar rates of response to therapy, but fewer Grade 3-4 AEs (0% vs. 28.5%) than dual therapy. Long-course therapy (> 4 cycles) resulted in radiographic response (p = 0.024) more often than a short-course (≤ 4 cycles), with similar AEs. Median follow-up duration was 19 months from surgery (range: 8-63).
Conclusion:
Critical insights into molecular therapeutic practice patterns for treatment of PCP were identified. Radiation-sparing, mono-therapeutic, and prolonged treatment duration are feasible options and warrant further study.
Insights
Targeted therapy for BRAF V600E mutant papillary craniopharyngioma (PCP) shows promise, with most patients responding. Radiation-sparing, monotherapy, and longer treatment durations are feasible options for this rare tumor.
Area of Science:
- Neuro-oncology
- Molecular targeted therapy
- Rare tumor treatment
Background:
- Papillary craniopharyngioma (PCP) with BRAF V600E mutation is rare.
- Limited guidance exists for targeted therapeutic use in PCP.
- Retrospective evaluation of current practice patterns is needed.
Purpose of the Study:
- To evaluate practice patterns for targeted therapeutics in BRAF V600E mutant PCP.
- To assess outcomes of targeted therapy in PCP treatment.
- To identify optimal therapeutic strategies for PCP.
Main Methods:
- Retrospective evaluation of practice patterns at RAPID institutions.
- Analysis of clinical, demographic, and treatment variables.
- Assessment of imaging response, adverse events, and salvage therapies.
Main Results:
- 72.2% of patients showed at least partial response to BRAF or BRAF/MEK inhibitors.
- No patients progressed on therapy; 47.4% discontinued due to adverse events.
- Radiation-sparing regimens and BRAF monotherapy showed comparable efficacy with fewer adverse events.
Conclusions:
- Targeted therapy is effective for BRAF V600E mutant PCP.
- Radiation-sparing, monotherapy, and prolonged treatment are feasible options.
- Further studies are warranted to confirm these findings.
